Edgar Filing: AGENUS INC - Form 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 File	ATEMENT OF CH d pursuant to Section n 17(a) of the Public	URITIES AND EXCHANGE Vashington, D.C. 20549 ANGES IN BENEFICIAL OW SECURITIES n 16(a) of the Securities Exchan e Utility Holding Company Act of Investment Company Act of 19	VNERSHIP OF ge Act of 1934, of 1935 or Section	OMB Number: Expires: Estimated burden ho response.	ours per	
(Print or Type Responses)						
1. Name and Address of Rep ARMEN GARO H	Symt	suer Name and Ticker or Trading ol ENUS INC [AGEN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Mo		te of Earliest Transaction th/Day/Year) 1/2013	Director 10% Owner X Officer (give title Other (specify below) below) Chairman & CEO			
(Street) LEXINGTON, MA 024	Filed	f Amendment, Date Original ed(Month/Day/Year)			Person	
(City) (State)	(Zip)	Cable I - Non-Derivative Securities Action	quired, Disposed of	, or Benefici	ally Owned	
1.Title of 2. Transaction Security (Month/Day/ (Instr. 3)	a Date 2A. Deemed (ear) Execution Date, any (Month/Day/Yea	Code (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common 07/01/2013 Stock		$J_{(1)}^{(1)}$ 3,515 A $\begin{array}{c} \$\\ 3.7545 \end{array}$	5 1,044,602	D		
Common Stock			796,168	Ι	by Trusts and Antigenics Holdings (2)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: AGENUS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	7. Titl Amou Under Secur (Instr.	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
ARMEN GARO H 3 FORBES ROAD LEXINGTON, MA 02421			Chairman & CE	0			
Signatures							
Christine M. Klaskin, by Power of Attorney		07/02/2013					
**Signature of Reporting Person			Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents issuance of stock for payment of approximately 33% of Dr. Armen's salary for June 2013.

Dr. Armen is trustee and has investment authority for the Garo Armen 2009 4 Year GRAT and the Garo Armen 2012 2 Year GRAT, holding 292,122 and 500,000 shares of Agenus Inc. common stock, respectively Dr. Armen disclaims beneficial ownership therein. Dr.

(2) Armen is also Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.